Castration-induced reduction of vascular endothelial growth factor expression in benign human prostate tissue is lost in advanced prostate cancer

BJU International

Volumn 88, Issue 1, 2001, Pages 110-116

  Haggstrom S ^a   Stattin, P ^a   Wikstrom P ^a   Bergh, A ^a   Damber, J E ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apoptosis; Endothelial cell; Human prostate cancer; VEGF

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; CASTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE; TUMOR CELL; TUMOR LOCALIZATION;

APOPTOSIS; BIOPSY; CASTRATION; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035732979     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2001.02234.x     Document Type: Article

References (45)

1. Studies on prostatic cancer. II. The effects of castration on adjuvanced carcinoma of the prostate gland
2. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
3. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration
4. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors
5. Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer
6. Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: A review
7. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration
8. Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival
9. Early effects of castration on the vascular system of the rat ventral prostate gland
10. Transient ischemia induces apoptosis in the ventral prostate of the rat
11. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats
12. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with a reduction of prostatic nitric oxide synthase activity
13. Adrenomedullin gene is abundantly expressed and directly regulated by androgen in the rat ventral prostate
14. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration
15. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats
16. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens
17. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
18. Localization of type 5,17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry
19. Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen
20. A novel function of VEGF receptor-2 (KDR): Rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells
21. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
22. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: In situ and in vitro expression of VEGF by human prostate cancer cells
23. Expression of vascular endothelial growth factor receptors in human prostate cancer
24. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human carcinoma micro tumours in vivo
25. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy
26. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
27. Castration rapidly results in a major reduction in epithelial cell numbers in the rat prostate but not in the highly differentiated Dunning R3327 prostatic adenocarcinoma
28. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat
29. Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumour cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients
30. Tumor induction of VEGF promoter activity in stromal cells
31. Deletion of cells by apoptosis during castration-induced involution of the rat prostate
32. Expression of transforming growth factor-B receptor type I and II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment
33. Angiogenic peptides in prostatic disease
34. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer
35. Is tissue mass regulated by vascular endothelial cells? Prostate as the first evidence
36. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
37. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: Correlation with clinicopathology and patient survival, and analysis of serum VEGF levels
38. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
39. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia
40. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
41. Vascular endothelial growth factor content in metastasizing and non metastasizing Dunning prostatic adenocarcinoma
42. Elevated levels of angiogenic cytokines in the plasma of cancer patients
43. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
44. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology